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ABSTRACT
Extracellular vesicles (EV) are increasingly being recognized as important vehicles of intercellular
communication and promising diagnostic and prognostic biomarkers in cancer. Despite this
enormous clinical potential, the plethora of methods to separate EV from biofluids, providing
material of highly variable purity, and lacking knowledge regarding methodological repeatability
pose a barrier to clinical translation. Urine is considered an ideal proximal fluid for the study of EV
in urological cancers due to its direct contact with the urogenital system. We demonstrate that
density-based fractionation of urine by bottom-up Optiprep density gradient centrifugation
separates EV and soluble proteins with high specificity and repeatability. Mass spectrometry-
based proteomic analysis of urinary EV (uEV) in men with benign and malignant prostate disease
allowed us to significantly expand the known human uEV proteome with high specificity and
identifies a unique biological profile in prostate cancer not uncovered by the analysis of soluble
proteins. In addition, profiling the proteome of EV separated from prostate tumour conditioned
medium and matched uEV confirms the specificity of the identified uEV proteome for prostate
cancer. Finally, a comparative proteomic analysis with uEV from patients with bladder and renal
cancer provided additional evidence of the selective enrichment of protein signatures in uEV
reflecting their respective cancer tissues of origin. In conclusion, this study identifies hundreds of
previously undetected proteins in uEV of prostate cancer patients and provides a powerful
toolbox to map uEV content and contaminants ultimately allowing biomarker discovery in
urological cancers.
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Introduction
Prostate cancer is the most commonly diagnosed
male malignancy in developed countries and the
third leading cause of cancer-related mortality [1,2].
An important clinical problem in prostate cancer is
the inability of current diagnostic tests to discrimi-
nate between indolent and aggressive cancers [3],
leading to overdiagnosis and overtreatment [4]. As
a result, there is an intense interest in finding bio-
markers that improve clinical decision-making in
prostate cancer. Despite the high clinical need, only
few have been accepted for diagnosis or follow-up in
guidelines or routine clinical practice and uncer-
tainty regarding reliability, clinical utility and cost-
effectiveness hinder their widespread use [5].
Although still in its infancy compared to the study of
circulating tumour cells (CTC) and DNA (ctDNA), the
biological role and clinical potential of extracellular vesi-
cles (EV) in cancer have been the focus of increasing
scientific interest. Cancer initiation and progression are
dependent on the ability of cells to communicate with
their local and distant environment through secretory
products such as EV, a heterogeneous group of bi-
layered, nanometre-sized membrane vesicles, released
into the extracellular space by multiple cell types [6].
They are composed of distinct repertoires of proteins,
nucleic acids, lipids and metabolites, and their cargo is
controlled by specific molecular sorting machineries [7].
In addition to their availability in multiple body fluids,
several aspects make them appealing from a biomarker
perspective. Their cargo is a spatiotemporal fingerprint
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of the cell of origin and a reflection of the pathophysio-
logical processes occurring within the source tissue.
Moreover, due to their multidimensional cargo, multiple
options for biomarker detection exist within the same
entity [5]. However, translating EV content into cancer
biomarkers remains challenging due to the difficulty of
obtaining high-purity EV from complex biological
matrices [8]. Urine directly reflects changes in the
pathophysiological status of the urogenital system due
to its exposure to renal and urothelial cells and prostatic
secretions, making it an attractive biofluid for cancer
biomarker discovery. However, protein abundance in
this matrix spans over five orders of magnitude, with
the 20 most abundant proteins, such as high molecular-
weight Tamm-Horsfall Protein (THP/UMOD) polymers
and albumin, accounting for 50% of the total protein
mass [9]. These proteins are co-isolated as
a contaminant in urinary EV (uEV) preparations and
dominate liquid chromatography–mass spectrometry
(LC-MS/MS) analysis, limiting detection of low-
abundance uEV proteins. In addition, THP entraps non-
EV associated extracellular RNA molecules [10].
Therefore, appropriate steps to control the presence of
highly abundant soluble proteins in purified uEV pre-
parations is mandatory to minimize confounding influ-
ence of non-EV signals [11]. An efficient and repeatable
procedure to separate EV from contaminants is
a prerequisite to obtain reliable omics data for clinical
and research applications. Our recent review of the
literature identified 34 distinct EV separation protocols
in 131 studies performed on urine, indicating the
absence of standardized protocols [5,12]. Although
rigour and standardization are the subject of increasing
attention in EV research [8,13–16], repeatability of EV
separation from biofluids, as well as the content of the
biofluid devoid of EV, have been poorly investigated
before researching disease-associated EV-biomarkers
[13].
This study presents a floatation-based density gradi-
ent protocol to separate EV from urine with minimal
THP and soluble protein contamination. This
approach is highly repeatable and enables the analysis
of EV-enriched and protein-enriched fractions in urine
from cancer patients. We applied this protocol to clini-
cally relevant urine samples from patients with prostate
cancer (prior to and after treatment) and benign pro-
static hyperplasia (BPH). Differential quantitative pro-
teomic analysis of EV-enriched and protein-enriched
urine fractions, identified the enrichment of unique
and biologically and clinically relevant proteomes in
uEV. In addition, by profiling matched prostate cancer
tissue-derived EV and uEV, we demonstrated that the
uEV proteome is a reflection of that of the tissue EV of
origin. This work presents a thoroughly substantiated
case favouring the study of uEV as a source of unique
biological and disease profiles not uncovered by the
conventional analysis of crude urine samples.
Materials & methods
Antibodies
The following antibodies were used for immunostaining:
anti-Alix (1:1000 (0.10 µg/mL), 2171 S, Cell Signaling
Technology, Beverly, MA, USA), anti-TSG101 (1:1000
(0.20 µg/mL), sc-7964, Santa Cruz Biotechnology,
Dallas, Texas, USA), anti-CD9 (1:1000 (0.23 µg/mL),
D3H4P, Cell Signaling Technology), anti-Flotillin-1
(1:1000 (0.25 µg/mL), 610820, BD Biosciences, Franklin
Lakes, NJ, USA), anti-Syntenin-1 (1:1000 (0.11 µg/mL),
ab133267, Abcam, Cambridge, UK), anti-THP (1:800
(0.25 µg/mL), sc-20631, Santa Cruz Biotechnology), anti-
GM130 (1:500 (0.50 µg/mL), 610822, BD Biosciences),
anti-PMP70 (1:2000 (0.50 µg/mL), P0497, Sigma-
Aldrich, St. Louis, MO, USA), anti-green fluorescent
protein (GFP) (1:1000 (0.10 µg/mL), MAB3580, Merck
Millipore, Billerica, MA, USA), anti-PSA/KLK3 (1:1000
(0.11 µg/mL), D11E1, Cell Signaling Technology),
anti-Rab27a (1:1000 (0.40 μg/mL), HPA001333,
Sigma-Aldrich), anti-FASN (1:1000 (0.40 μg/mL),
HPA056108, Sigma-Aldrich), anti-IDH1 (1:1000
(1.0 μg/mL), AMAB90578, Sigma-Aldrich), anti-AQP2
(1:1000 (1.0 μg/mL), PA5-38004, ThermoFisher
Scientific, Waltham, MA, USA), anti-PODXL (1:1000
(0.43 µg/mL), ab150358, Abcam), anti-SLC12A1 (1:500
(2.0 μg/mL), SAB1402357, Sigma-Aldrich, anti-UPK1B
(1:400 (0.25 μg/mL), HPA031800, Sigma-Aldrich), sheep
anti-mouse horseradish peroxidase-linked antibody
(1:3000 (0.14 μg/mL), NA931 V, GE Healthcare life
sciences, Uppsala, Sweden), donkey anti-rabbit horserad-
ish peroxidase-linked antibody (1:4000 (0.05 μg/mL),
NA934V, GE Healthcare life sciences).
Patients and biological sample collection
Matched urine samples were collected from prostate
cancer patients prior to (n = 12) and 3 months after
local treatment by radical prostatectomy or intensity-
modulated radiation therapy (n = 10). From selected
prostate cancer patients (PC; n = 3), urine samples
prior to radical prostatectomy and resected prostate
cancer tissue samples were collected. In addition,
urine samples from healthy controls with BPH
(n = 12) and patients diagnosed with urothelial cancer
of the bladder (UCC; n = 5) or renal cell carcinoma
(RCC; n = 6) were collected prior to treatment. For
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technical experiments, healthy donor urine samples
were used. All samples were second morning whole
void urine samples from fasting donors. Pre-
treatment prostate cancer samples and BPH control
samples were collected immediately following digital
rectal examination (DRE), which was performed as 3
finger strokes per prostate lobe. Collection of biological
samples was according to the Ethical Committee of
Ghent University Hospital approval EC/2015/0260
and in accordance with the guidelines and regulations
of the Helsinki Declaration. Participants provided writ-
ten informed consent.
Values for urinary pH, specific gravity (SG), glucose
(GLU), bilirubin (BIL), ketones (KET), blood (BLO), pro-
tein (PRO), urobilinogen (URO), nitrite (NIT) and leuko-
cytes (LEU) were analysed with a Multistix 10SG strip-test
(Siemens Healthcare, Erlangen, Germany), and these were
within normal ranges (pH: 6–7.5; SG: 1.010–1.030; GLU:
negative; BIL: negative; KET: negative; BLO: 0–10 erythro-
cytes/µL; PRO: 0–20 mg/dL; URO: 3.2–16 µmol/L; NIT:
negative; LEU: negative). Creatinine was measured using
the UC-3500 urine chemistry analyser (Sysmex, Kobe,
Japan). Urine samples (50 mL) were centrifuged for
10 min at 1000 g and 4°C (with braking) in accordance
with the Eurokup/HKUPP Guidelines [17] using an
Eppendorf 5810R (Eppendorf, Hamburg, Germany)
benchtop centrifuge with A-4-62 swinging bucket rotor.
Cell-free urine supernatants were collected (leaving
approximately 0.5 cmurine above the cell pellet) and stored
for up to 12 months at −80°C until further use. Detailed
patient characteristics and clinical data are summarized in
Suppl. table 1.
Urine fractionation by bottom-up Optiprep density
gradient centrifugation
Cell-free urine samples (50 mL) were thawed at room
temperature, vortexed and concentrated to
500–800 µL using a 10 kDa centrifugal filter device
(Centricon Plus-70, Merck Millipore). The concen-
trated sample was resuspended in Tris buffer contain-
ing 10 mM Tris-HCl (pH 7.4), 1 mM EDTA and
0.25 M sucrose to obtain a sample volume of 800 µL.
Solutions of 5%, 10% and 20% iodixanol were made
by mixing appropriate amounts of homogenization
buffer (0.25 M sucrose, 1 mM EDTA, 10 mM Tris-
HCL (pH 7.4)) and iodixanol working solution. This
working solution was prepared by combining
a working solution buffer (0.25 M sucrose, 6 mM
EDTA, 60 mM Tris-HCl, pH 7.4) and a stock solution
of OptiPrep (60% (w/v) aqueous iodixanol solution,
Axis-Shield, Oslo, Norway). The 800 µL concentrated
urine sample was resuspended in 3.2 mL working
solution, obtaining a 40% iodixanol suspension, and
layered on the bottom of a 17 mL Thinwall
Polypropylene Tube (Beckman Coulter, Fullerton,
CA, USA). A discontinuous bottom-up OptiPrep den-
sity gradient (ODG) was prepared by overlaying the
urine suspension with 4 mL 20%, 4 mL 10% and 3.5
mL 5% iodixanol solutions, and 1 mL PBS, respec-
tively. Gradient layering was performed by a Biomek
4000 pipetting robot using a custom-made script. The
ODG was centrifuged for 18 h at 100,000 g (accelera-
tion: max; deceleration: 9) and 4°C (SW 32.1 Ti rotor
with ravg = 11.36 cm and adjusted k-factor = 298.0,
Beckman Coulter). Afterwards, ODG fractions of
1 mL were collected from the top of the gradient
and pooled (1–5, 6–8, 9–10, 11–12, 13–14, 15–16),
diluted to 16 mL in PBS in a 17 mL Thinwall
Polypropylene Tube (Beckman Coulter) and centri-
fuged for 3 h at 100,000 g (acceleration: max; decel-
eration: max) and 4°C (SW 32.1 Ti rotor with ravg
= 11.36 cm and adjusted k-factor = 298.0, Beckman
Coulter). The resulting pellets were re-suspended in
100 µL PBS and stored at −80°C. For mass spectro-
metry-based proteomic experiments, pooled EV-rich
fractions 9–10, corresponding to a density of 1.087–-
1.109 g/mL were used for subsequent size exclusion
chromatography (SEC)-based separation of EV from
iodixanol as an alternative to pelleting by ultracentri-
fugation, increasing EV recovery [18,19]. To prepare
the SEC column, Sepharose CL-2B (GE Healthcare life
sciences) was washed three times by sedimentation in
PBS buffer. A nylon net with 20 μm pore size
(NY2002500, Merck Millipore) was placed on the
bottom of a 10 mL syringe (BD Biosciences, San
Jose, CA, USA), followed by stacking of 10 mL washed
Sepharose. After adding ODG fractions 9–10, indivi-
dual fractions of 1 mL eluate were collected. EV-
containing fractions 4–7 were pooled and concen-
trated to 100 µL using Amicon Ultra-2 10K filters
(Merck Millipore) and stored at −80°C until
further use.
Tumour conditioned medium (TCM) generation and
TCM EV separation
Resected prostate cancer tissue specimens were trans-
ported in PBS buffer and processed within 2 h of surgery.
The tumour tissue was manually sliced to pieces of
2–3 mm3 with sterile surgical scissors. These pieces
were washed by placing them on a 70 μm cell strainer
and gently flushing three times with 5mL of PBS buffer at
37°C. The pieces were weighed and then added to a well
of a 6-well plate, containing 2 mL of PBS buffer with 40%
DMEM containing 0.5% EV-depleted serum (EDS). EDS
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was obtained by centrifuging (acceleration: max; decel-
eration: 9) foetal bovine serum at 100,000 g (SW 32.1 Ti
rotor with ravg = 11.36 cm and adjusted k-factor = 298.0,
Beckman Coulter) for 16 h at 4°C followed by 0.2 μm
filtration. The plate was incubated for 3 h on a rotating
device at 37°C and 5% CO2. After incubation, tissue
pieces were recovered and kept for histology to assess
tissue viability. Tissue was fixed in 4% buffered formol for
12 h, followed by a wash with PBS and transfer to 70%
ethanol, and then embedded in paraffin, sectioned and
stained with haematoxylin and eosin. Tissue viability
after incubation was defined as the presence of normal
and/or malignant glandular and stromal structures in the
absence of ischaemic necrosis.
The supernatant, i.e. TCM, was centrifuged 10 min
at 200 g and 20 min at 2000 g (with braking) using an
Eppendorf 5810R benchtop centrifuge with A-4-62
swinging bucket rotor to remove cells and cell debris.
After the final centrifugation step, supernatant was
collected and kept at −80°C until EV separation. Only
TCM from viable tissue samples was used for subse-
quent EV separation and analyses.
A combination of SEC and top-downODGwas used to
separate EV from TCM [20,21]. After thawing, TCM
(2 mL) was placed on top of a SEC column, followed by
elution by PBS and collection of individual fractions of
1 mL eluate. EV-containing fractions 4–7 were pooled
and concentrated to 1mL usingAmiconUltra-2 10K filters
(Merck Millipore). Subsequently, a discontinuous top-
down ODG was used as described previously [22].
Solutions of 5%, 10%, 20% and 40% iodixanol were made
by mixing appropriate amounts of homogenization buffer
and iodixanol working solution, as described above. The
gradientwas formed by layering 4mLof 40%, 4mLof 20%,
4 mL of 10% and 3.5 mL of 5% solutions on top of each
other in a 17 mL Thinwall Polypropylene Tube (Beckman
Coulter). Gradient layering was performed by a Biomek
4000 pipetting robot using a custom-made script. The 1mL
concentrated SEC sample was overlaid on top of the gra-
dient, which was then centrifuged for 18 h at 100,000 g
(acceleration: max; deceleration: 9) and 4°C (SW 32.1 Ti
rotor with ravg = 11.36 cm and adjusted k-factor = 298.0,
Beckman Coulter). Gradient fractions of 1 mL were col-
lected starting from the top of the gradient. Fractions 9 and
10, corresponding to a density of 1.087–1.109 g/mL, were
pooled and used for subsequent SEC-based separation of
EV from the iodixanol polymer, as described above. EV
samples were stored at −80°C until further use.
Density measurement
Density of the ODG fractions was assessed using
a standard curve of the absorbance values at 340 nm
(SpectraMax Paradigm, Molecular Devices, San Jose,
CA, USA) of aqueous dilutions of 5%, 10%, 20% and
40% iodixanol solutions (solutions were diluted 1:1
twice). This standard curve was used to determine the
density of fractions collected from a control gradient.
Urinary EV separation by differential
ultracentrifugation
Differential ultracentrifugation was performed as
described previously by Théry et al. [23]. Cell-free urine
samples (50 mL) were thawed at room temperature and
vortexed before processing. Next, urine was centrifuged for
30 min at 2000 g (with braking) and 4°C in an Eppendorf
5810R benchtop centrifuge with A-4-62 swinging bucket
rotor. The supernatant was transferred to a 38.5 mL
Thinwall Polypropylene Tube (BeckmanCoulter) and sub-
jected to serial ultracentrifugation (acceleration: max;
deceleration: max) at 4°C at 12,000 g (SW 32.1 Ti rotor
with ravg = 11.36 cm and adjusted k-factor = 2483.31,
Beckman Coulter) and 110,000 g (SW 32.1 Ti rotor with
ravg = 11.36 cm and adjusted k-factor = 270.91, Beckman
Coulter), for 45 min and 2 h, respectively. The crude pellet
was resuspended in 16 mL PBS and passed through
a 0.22 µm Whatman syringe filter (GE Healthcare life
sciences) and EV were pelleted in a 17 mL Thinwall
Polypropylene Tube (Beckman Coulter) by centrifugation
at 110,000 g (acceleration:max; deceleration:max) and 4°C
for 70 min. An additional washing step was performed by
repeating the previous resuspension and pelleting step.
The final pellet was re-suspended in 100 µL PBS and stored
at −80°C until further use.
Urinary EV separation by Exoquick precipitation
Exoquick-TC (System Biosciences, Palo Alto, CA, USA)
was used according to the manufacturer’s instructions.
Cell-free urine samples (50 mL) were thawed at room
temperature, vortexed before being concentrated to
500 µL using a 10 kDa centrifugal filter device
(Centricon Plus-70, Merck Millipore) and mixed with
100 µL of Exoquick-TC solution. The sample was incu-
bated overnight at 4°C after which it was spun down twice
at 1500 g (with braking) in an Eppendorf 5810R benchtop
centrifuge with A-4-62 swinging bucket rotor for 30 and
5 min, respectively. The pellet was resuspended in 100 µL
of PBS and stored at −80°C until further use.
Urinary EV separation by size-exclusion
chromatography
SEC was performed as described previously [24]. Cell-
free urine samples (50 mL) were thawed at room
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temperature and vortexed followed by concentration to
1 mL using a 10 kDa centrifugal filter device
(Centricon Plus-70, Merck Millipore). To prepare the
SEC column, Sepharose CL-2B (GE Healthcare life
sciences) was washed three times by sedimentation in
PBS buffer. A nylon net with 20 μm pore size
(NY2002500, Merck Millipore) was placed on the bot-
tom of a 10 mL syringe (BD Biosciences), followed by
stacking of 10 mL washed Sepharose. After adding the
1 mL urine sample, followed by elution by PBS, indi-
vidual fractions of 1 mL eluate were collected until the
urine sample was completely eluted. Individual frac-
tions were stored at −80°C until further use.
Urinary EV separation by top-down Optiprep
density gradient centrifugation
Cell-free urine samples (50 mL) were thawed at room
temperature and vortexed before being concentrated to
1 mL using a 10 kDa centrifugal filter device (Centricon
Plus-70, MerckMillipore). The sample was loaded on top
of a discontinuous top-down ODG and processed as
described above.
Urinary THP depolymerization by DTT treatment
DTT treatment was performed as a modification of
a previously described protocol [25]. Cell-free urine
samples (50 mL) were thawed at room temperature
and vortexed before processing. Urine was trans-
ferred to a 38.5 mL Thinwall Polypropylene Tube
(Beckman Coulter) and centrifuged (acceleration:
max; deceleration: max) at 4°C and 17,000 g (SW
32.1 Ti rotor with ravg = 11.36 cm and adjusted
k-factor = 1752.92, Beckman Coulter) for 10 min to
pellet THP polymers. The supernatant was kept at 4°
C, while the resulting 1.5 mL pellet was incubated
with 1 mL of a freshly prepared dithiothreitol solu-
tion (50% DTT in aqua distilled) for 10 min at 37°C
and vortexed to depolymerize THP (final DTT con-
centration: 200 mg/mL). The treated pellet and pre-
vious supernatant were mixed in a 38.5 mL Thinwall
Polypropylene Tube (Beckman Coulter) and centri-
fuged again for 10 min at 17,000 g (acceleration: max;
deceleration: max) and 4°C.
The resulting supernatant was used for uEV separa-
tion by BU ODG, as described above.
Nanoparticle tracking analysis
ODG fractions were analysed by Nanoparticle tracking
analysis (NTA) using a NanoSight LM10-HS micro-
scope (Malvern Instruments Ltd, Amesbury, UK)
equipped with a 405 nm laser. For each sample, three
60 s videos were recorded at camera level 13. For
fluorescent NTA measurements (fNTA) a 488 nm
laser and an automatic syringe pump system (infusion
speed: 20) were used. An additional 500 nm longpass
filter was applied and the camera level was increased to
16. Temperature was monitored during recording.
Recorded videos were analysed at detection threshold
3 with NTA Software version 3.3 to determine the
concentration and size distribution of measured parti-
cles with corresponding standard error. A medium
viscosity of 0.929 cP was assumed. For optimal mea-
surements, samples were diluted with PBS until particle
concentration was within optimal concentration range
of the NTA Software (3 × 108−1 × 109). All size dis-
tributions determined with NTA correspond to the
hydrodynamic diameters of the particles in suspension.
Generation and spiking of recombinant
extracellular vesicles (rEV)
GFP-positive rEV were generated as previously
described [19] and spiked in urine to validate BU
ODG fractionation and calculate recovery efficiencies
of UF, SEC, EQ, DUC, TD ODG and BU ODG.
Protein analysis
Protein concentrations were measured using the
fluorometric Qubit Protein Assay (ThermoFisher
Scientific, Waltham, MA, USA). Sample preparation
was done by 1:1 dilution with SDS 0,4%. Protein mea-
surements were performed using the Qubit
Fluorometer 3.0 (ThermoFisher Scientific) according
to the manufacturer’s instructions.
Protein samples were dissolved in reducing sample
buffer (0.5 M Tris-HCl (pH 6.8), 40% glycerol, 9.2%
SDS, 3% 2-mercaptoethanol, 0.005% bromophenol
blue) and boiled at 95°C for 5 min in a thermomixer
at 900 rpm. Gel loading of proteins was based on the
same percentage of the final volume of the pellet/frac-
tion. Proteins were separated by SDS-PAGE (SDS-
polyacrylamide gel electrophoresis). SDS-PAGE gels
were produced by making a 10% acrylamide separating
gel solution (33% acrylamide 30% (Bio-rad, Hercules,
CA, USA), 25% separating buffer (0.4% SDS, 18.7%
Tris, 6 M HCl in aqua distilled (AD)), 41% AD, 1%
ammonium persulphate (APS) and 0.1% tetramethy-
lethylenediamine (TEMED)). The separating gel solu-
tion was casted between two glass electrophoresis slides
and allowed to polymerize for 30 min. To keep the gel
from drying out, 70% ethanol was added on top of the
gel. After polymerization, ethanol was removed and
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a stacking gel solution (15% acrylamide 30% (Bio-rad),
25% stacking buffer (0.4% SDS, 6% Tris, 6 M HCl
in AD) 1% APS and 0.1% TEMED) was added on top
of the separating gel. A comb was placed in between
the two glass slides to form the loading slots and the
stacking gel was allowed to harden for 30 min. Gels
were placed in a Mini-PROTEAN Tetra Vertical
Electrophoresis Cell (Bio-Rad). The electrophoresis
cell was filled with running buffer (0.3% glycine,
1.44% Tris, 0.1% SDS in AD) and loaded protein sam-
ples and Pageruler prestained protein ladder (Thermo
Fisher Scientific) were separated by application of an
electric field of 150 V for 60 min. SDS-PAGE gels
containing separated proteins were placed in a gel
holder cassette and submerged (wet blotting system)
in a Criterion Blotter Buffer Tank (Bio-rad) filled with
blotting buffer (0.3% glycine, 1.44% Tris, 0.00005%
SDS, 20% methanol in AD). Proteins were transferred
to a nitrocellulose membrane (Bio-rad) by application
of an electric field of 100 V for 45 min. Next, using
a molecular weight (MW) ladder as a reference, nitro-
cellulose membranes were cut into horizontal strips
according to the MW of the protein of interest (1
protein per strip) and submerged in blocking buffer
(5% non-fat milk powder and 0.5% Tween-20 in
PBSD−) for 30 min. Blocked membranes were immu-
nostained overnight at 4°C with primary antibodies.
Secondary antibodies were added for 60 min at room
temperature after extensive washing with blocking buf-
fer. After final washing, chemiluminescence substrate
(WesternBright Sirius, Advansta, Menlo Park, CA,
USA) was added and imaging was performed using
the Proxima 2850 Imager (IsoGen Life Sciences, De
Meern, The Netherlands). Quantification of signal
intensity was performed using ImageJ software [26].
Alternatively, separated proteins were stained with
Coomassie Brilliant Blue R-250 Staining Solution (Bio-
Rad) for 60 min and destained overnight at 4°C in
a solution composed of 40% methanol and 10% acetic
acid.
Transmission electron microscopy
Samples were qualitatively analysed with transmission
electron microscopy (TEM). Samples were deposited on
a formvar coated grids stabilized with evaporated carbon
film and glow discharged before sample application.
Neutral uranyl acetate (2% in AD) was used for staining
after which grids were coated with 2% methyl cellulose/
uranyl acetate (0,4%) solution. These grids were exam-
ined using a Tecnai G2 Spirit transmission electron
microscope (FEI, Eindhoven, The Netherlands) operated
at 100 kV and images were captured with a Quemesa
charge-coupled device camera (Olympus Soft Imaging
Solutions GMBH, Munster, Germany).
LC-MS/MS
Samples were processed for LC-MS/MS by filter-aided
sample preparation (FASP) [27]. Lysates were prepared
by mixing samples with SDT-lysis buffer (2% SDS,
500 mM Tris-HCL (pH 7.6), 0.5 M DTT) at a 4:1
sample to buffer ratio and incubated at 95°C for
5 min. After clarification of lysates by centrifugation
(16,000 g for 5 min), samples were mixed with 300 μL
UA (8 M urea, 0.1 M Tris-HCl (pH 8.5)) in a Microcon
YM-10 centrifugal filter device (Merck KGaA,
Darmstadt, Germany). Filters were centrifuged twice
(14,000 g for 40 min at 20°C) with the addition of
200 µL UA in between. Proteins were alkylated by
addition of 100 μL IAA solution (0.05 M iodoaceta-
mide in UA buffer) and incubated for 30 min at room
temperature, followed by centrifugation. This was fol-
lowed twice by addition of 100 µL UA and twice by
addition of 100 µL DB buffer (1 M urea, 0.1 M Tris-
HCl (pH 8.5), with centrifugation in between. Filter
units were transferred to new collection tubes and
proteins were resuspended in 40 µL DB with Trypsin/
Lys-C mix (Promega, Madison, WI, USA) for over-
night proteolytic digestion at 37°C. Digests were col-
lected by addition of 100 µL DB and centrifugation for
15 min at 14,000 g. This step was repeated once.
Collected peptides were acidified with 1% trifluoroace-
tic acid to a pH of 2–3, followed by desalting with C18-
StageTips (C18 Empore Disks, 3 M, St. Paul, MN,
USA). Desalted peptides were vacuum dried, dissolved
in 0.1% formic acid and analysed by LC-MS/MS. Equal
amounts of peptides of each sample (500 ng) were
loaded on a nanoflow HPLC system (Easy-nLC1000,
Thermo Fisher Scientific) coupled to a Q Exactive HF
Hybrid Quadrupole-Orbitrap Mass Spectrometer
(Thermo Fisher Scientific) equipped with a nano-elec-
trospray ionization source. The mobile phase consisted
of 0.1% formic acid (solvent A) and acetonitrile/water
(95:5 (v/v)) with 0.1% formic acid (solvent B). The
peptides were separated with a 50-min gradient from
8% to 35% of solvent B. Before the end of the run, the
percentage of solvent B was raised to 100% in 5 min
and kept there for 5 min. Full MS scan over the mass-
to-charge (m/z) range of 300–1750 with a resolution of
120,000, followed by data dependent acquisition with
an isolation window of 2.0 m/z and a dynamic exclu-
sion time of 30 s was performed. The top 12 ions were
fragmented by higher energy collisional dissociation
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(HCD) with a normalized collision energy of 27% and
scanned over the m/z range of 200–2000 with
a resolution of 15,000. After the MS2 scan for each of
the top 12 ions had been obtained, a new full mass
spectrum scan was acquired and the process repeated
until the end of the 60 min run. Three repeated runs
per sample were performed. Tandem mass spectra were
searched using the MaxQuant software (version
1.5.2.8) against a database containing both reviewed
(SwissProt) and unreviewed (TrEMBL) sequences of
homo sapiens, including different isoforms, of
UniProtKB release 2018_07. Peptide-spectrum-match-
and protein-level false discovery rates were set at 0.01.
Carbamidomethyl (C), as a fixed modification, and
oxidation (M) and acetylation of the protein
N-terminus as dynamic modifications were included.
A maximum of two missed cleavages was allowed. The
LC-MS profiles were aligned, and the identifications
were transferred to non-sequenced or non-identified
MS features in other LC-MS runs (matching between
runs). The protein was determined as detected in the
sample if its identification had been derived from at
least two unique peptide identifications. Filtering for
contaminating proteins, reverse identification and
identification by site was used. Label-free quantifica-
tion (LFQ) was performed using the MaxLFQ algo-
rithm integrated into the MaxQuant software. The
mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium [28] via the
PRIDE [29] partner repository with the dataset identi-
fier PXD015289.
Proteomic data analysis
Identified proteins were analysed and visualized using
Perseus software version 1.6.2.2 [30]. For comparison
between prostate cancer and benign prostate hyper-
plasia samples, intensities of proteins were normalized
to the prostate-specific marker KLK3/PSA [31].
Proteins showing valid values in at least 70% of at
least one group were selected. Missing values were
imputed from the observed normal distribution of
intensities. For selected analyses, intensities were
transformed to z-scores. Unsupervised hierarchical
clustering heat maps, using 1-Pearson correlation,
were generated using the Morpheus tool. Anosim
and principle component analysis were performed
using Past3 software [32]. Differences of the mean
were evaluated by Student’s t-test with permutation-
based false discovery rate (FDR) estimation and
q-values smaller than 0.05 were considered statisti-
cally significant. Volcano plots were generated with
S0 set at 0.1. Pathway enrichment analysis was
performed using g:Profiler [33] and data were visua-
lized using Cytoscape and the EnrichmentMap pipe-
line [34], as previously described [35]. The
Vesiclepedia database was explored and Venn dia-
grams were generated using Funrich software version
3.1.3 [36].
Statistical analysis
Data analysis and visualization was performed using
GraphPad Prism version 6 (GraphPad Software, San
Diego, CA, USA). Data are expressed as median with
interquartile range (IQR). Correlations were calculated
using the Pearson product-moment (r) or Spearman
rank-order (ρ) correlation method, as indicated in the
text. P-values smaller than 0.05 were considered statis-
tically significant.
EV-TRACK
We have submitted all relevant data of our experiments
to the EV-TRACK knowledgebase (EV-TRACK ID:
EV190064) [12].
Data availability
Themass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE
partner repository with the dataset identifier PXD015289.
We have submitted all relevant data of our experiments to
the EV-TRACK knowledgebase (EV-TRACK ID:
EV190064). Full-length western blots for Figures 1 and
8 and Suppl. figs. 2, 3, 4 and 7 are provided in Suppl.
Appendix 1.
Results
Differential ultracentrifugation, Exoquick
precipitation and size-exclusion chromatography
separate EV from urine with low specificity
Mining of the EV-TRACK knowledgebase [12]
revealed that urine is a frequently explored biofluid in
the search for biomarkers (Suppl. fig. 1a) and that
differential ultracentrifugation (DUC), size-exclusion
chromatography (SEC) and commercial precipitation-
based methods such as Exoquick (EQ) are the most
commonly implemented EV separation methods to
achieve this (Suppl. fig. 1b). Considering the unique
physicochemical properties of urine, we compared the
performance of these methods to separate uEV using
complementary particle- and protein-based measure-
ment methods. A single pool of cell-free urine from
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Figure 1. Characterization of urine fractionated by top down (TD) versus bottom up (BU) Optiprep density gradient (ODG)
centrifugation. (a) Nanoparticle tracking analysis of EV-enriched fractions. NTA calculated size distributions are depicted as mean
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healthy donors was subjected to DUC, EQ and SEC
(Suppl. fig. 2). Although all methods recovered particles
within the size range of EV, as measured by nanopar-
ticle tracking analysis (NTA) (Suppl fig. 2a), the enrich-
ment of particles relative to co-isolated soluble proteins
differed (Suppl. fig. 2b). Western blot analysis revealed
that uEV samples obtained by DUC and EQ contain
EV-associated proteins ALIX and CD9, while Flotillin-
1 was barely detectable. All uEV preparations were
clear from contaminating cell organelles as indicated
by the absence of PMP70 and GM130. Coomassie blue
staining demonstrated co-separation of urinary high-
abundance proteins in EV separated by EQ, as indi-
cated by the presence of distinct protein bands for
Tamm-Horsfall Protein (THP; 105 kDa), albumin
(67 kDa) and IgG (heavy chain: 50 kDa and light
chain: 25 kDa), while EV separated from urine by
DUC mainly contained contaminating THP. This was
confirmed by western blot analysis (Suppl. fig. 2c). An
additional washing step in the DUC protocol decreased
the amount of THP but also resulted in significant loss
in particles and EV-associated proteins ALIX and CD9
(Suppl. fig. 2b,c), as observed previously [37]. Although
SEC separated uEV, characterised by ALIX, flotillin-1
and CD9, from the bulk of protein, THP polymers
remained present as shown by western blot and elec-
tron microscopy analysis (Suppl. fig. 2c,d). In summary,
the most commonly implemented separation methods
are suboptimal to separate uEV with high specificity.
Bottom-up density gradient centrifugation
separates EV from urine with high specificity
We explored density as an alternative dimension of phy-
sical particle separation. Urinary ultrafiltrates (UF) were
submitted to a discontinuous iodixanol (Optiprep) den-
sity gradient (ODG), either aiming for top-down (TD)
sedimentation or bottom-up (BU) floatation of uEV to
equilibrium density. ODG fractions with distinct physical
and biochemical characteristics were identified (Figure 1
(a–e)). Particles within the size range of EV (Figure 1(a))
and a density of 1.087–1.109 g/mL (Figure 1(b)) were
separated from soluble proteins by both TD and BU
ODG (Figure 1(c–d)). Coomassie blue staining identified
a distinct protein pattern in these fractions compared to
other ODG fractions. Independently of a TD or BU
approach, ODG fractions of 1.087–1.109 g/mL were posi-
tive for ALIX, TSG101, Flotillin-1 and CD9 (Figure 1(c))
and are therefore hereafter referred to as EV-enriched
fractions. All urine fractions were free from contaminat-
ing cell organelle markers PMP70 and GM130. In addi-
tion, Coomassie blue staining demonstrated separation of
EV-enriched proteins from major urinary contaminants,
as indicated by the absence of distinct protein bands for
THP (105 kDa), albumin (67 kDa) and IgG (heavy chain:
50 kDa and light chain: 25 kDa) in EV-enriched fractions
(Figure 1(c)). The TD ODG EV-enriched fraction con-
tained 17.58% of the total contaminating THP protein,
based on western blot signal intensity, which was reduced
to 2.49% using BU ODG. TEM identified extensive num-
bers of vesicular structures with a size between 30 and
150 nm, characteristic of EV, in EV-enriched fractions. In
addition, TEM analysis confirmed that EV-enriched frac-
tions obtained by TD ODG were contaminated with
polymeric networks of THP (Figure 1(d)). In contrast,
BU ODG resulted in EV-enriched fractions (1.087–
1.109 g/mL) that were efficiently separated from contam-
inating THP complexes (1.156–1.201 g/mL, hereafter
referred to as THP-enriched fraction) and other soluble
proteins (1.207–1.231 g/mL, hereafter referred to as pro-
tein-enriched fraction) (Figure 1(c,e)).
As described previously [25], treatment of urine with
a reducing agent (DTT) released residual uEV from the
THP meshwork (1.156–1.201 g/mL) in which they were
observed to be trapped, but this neither improved yield
nor purity of uEV separated by BU ODG (Figure 1(d);
Suppl. fig. 3). Finally, spiking spot urine with GFP-
positive recombinant EV (rEV) validated the BU ODG
workflow, as demonstrated by the enrichment of rEV in
1.087–1.109 g/mL fractions (Suppl fig. 4a-b). EV recovery
efficiency of BUODGwas compared to that of other uEV
separation (DUC, EQ, SEC and TD ODG) methods and
uEV pre-enrichment by ultrafiltration (UF) alone. This
was defined as the number of rEV detected by fNTA after
separation divided by the number of rEV spiked (4 ×
1010). Recovery efficiency of UF was nearly 60%, while
(black line) with standard error (red area) and total particle number, mean particle size and mode are shown for each EV-enriched
fraction (Fractions 9–10: 1.087–1.109 g/mL). (b) Particle-protein recovery measurements of BU and TD ODG separated urine fractions.
Fractions 1–5, 6–8, 9–10, 11–12, 13–14 and 15–16 were pooled and are indicated by their respective density range in the x-axis. EV-
enriched fractions are indicated by a black rectangle. (c) Coomassie blue staining and western blot analysis for EV- (ALIX, TSG-101,
CD9, Flotillin-1) and non-EV (THP, GM130, PMP70) associated proteins. EV-enriched fractions are indicated by a black rectangle. THP-
enriched (Fractions 13–14: 1.156–1.201 g/mL) and protein-enriched (Fractions 15–16: 1.2017–1.231 g/mL) fractions are indicated by
a grey rectangle. (d) Transmission electron microscopy of EV, THP and protein-enriched fractions. Low (scale bar: 1000 nm) and high
magnification images (scale bar: 200 nm) are provided. White arrows indicate EV, black arrows indicate THP polymers and grey
arrows indicate protein complexes. (e) Graphical overview of BU ODG fractionation strategy for urine, resulting in an EV-enriched,
THP-enriched and protein-enriched fraction.
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efficiencies of UF followed by SEC, EQ and ODG to
separate EV from urine were, respectively, nearly 60%,
30% and 30%. Recovery of EV from EV-enriched ODG
density fractions 1.087–1.109 g/mL by a 100,000 g pellet-
ing step instead of SEC was halved from 30% to 15%.
DUC recovered only 5% of EV from urine. This was
further reduced to 1% after addition of a washing step
(Suppl fig. 4c).
In summary, BU ODG allowed the separation of
urine into three fractions of interest for biomarker
discovery: EV-enriched (1.087–1.109 g/mL), THP-
enriched (1.156–1.201 g/mL) and protein-enriched (1.-
207–1.231 g/mL) (Figure 1(e)).
Bottom-up density gradient separation of urine
reveals biologically relevant proteomes with high
repeatability
Technical replicates (n = 6) derived from a pool of cell-
free urine collected from prostate cancer patients post-
DRE were subjected to BU ODG separation and EV-
enriched, THP-enriched and protein-enriched fractions
(Figure 1(e)) were analysed by mass spectrometry-
based proteomics (LC-
MS/MS). Correlation analysis based on LFQ intensities
revealed high similarity within these fractions with
median Pearson’s r coefficients for EV-enriched of
0.97; for THP-enriched of 0.93; and for protein-
enriched of 0.93. Significant differences were observed
between EV-enriched and both THP- and protein-
enriched fractions with median Pearson’s
r coefficients down to 0.51 and −0.08, respectively
(Figure 2(a)). These observations were confirmed by
anosim analysis (R = 1, p = 0.0001) (Figure 2(b)).
Technical and methodological repeatability were
assessed by unsupervised hierarchical clustering and
principal component analysis (PCA). Both analyses
showed differential clustering of the three fractions of
interest with high similarity of the technical replicates
within each cluster (Figure 2(c,d)). With a median coeffi-
cient of variation of 0.008 (IQR: 0.005–0.024), 0.019
(IQR: 0.009–0.033) and 0.028 (IQR: 0.013–0.040) for the
EV-enriched, THP-enriched and protein-enriched frac-
tions, BU ODG yielded highly repeatable urinary
proteomes.
LC-MS/MS repeatedly identified 2333 unique proteins
over the three BU ODG fractions of interest (Figure 2(e);
Suppl. table 2), of which only 533 (22.86%) were shared
between EV and protein-enriched fractions. Of all the
identified proteins, 623 (26.7%) were exclusive to the EV-
enriched fraction, and this fraction contained 1313
(56.30%) proteins not identified in the protein-enriched
fraction. Conversely, 171 (7.33%) unique proteins were
identified in the protein-enriched fraction and this fraction
contained 417 (17.88%) proteins not identified in the EV-
enriched fraction. The THP-enriched fraction contained
almost nouniqueproteins (70; 3.00%) indicating that this is
a transition fraction between EV-enriched and protein-
enriched fractions, as demonstrated by plotting spectral
counts for EV-associated proteins and urinary high abun-
dance proteins for the three fraction types (Figure 2(f)).
Volcano plot analysis and Z-score analysis showed
a differential protein enrichment between the different
BUODG fractions and visualized the relative distribution
of multiple proteins of interest (Figure 2(g); Suppl fig. 5).
Differential protein enrichment between EV-enriched
and protein-enriched BU ODG fractions was also
reflected in the distribution of known prostate cancer
markers (EV-enriched: FOLH1, TMPRSS2, PSCA;
Protein-enriched: KLK3/PSA, ACPP), hinting towards
biological and clinical relevance of different urine
fractions.
Next, Gene Ontology (GO) analysis for biological
function of differentially enriched proteins was per-
formed. Functions related to EV biogenesis, protein and
nucleic acid metabolism, signalling and cytoskeleton
homeostasis were enriched in the EV-enriched fractions.
In contrast, cell adhesion, proteolysis, innate immune
response, platelet degranulation and extracellular matrix
organization pathways were enriched in protein-enriched
fractions (Figure 3). These differences were also reflected
in the cellular location of these proteins, with EV-
enriched proteins mainly being derived from cellular
membranes and the cytosol and the protein-enriched
fraction consisting of secreted and extracellular matrix
proteins (Suppl. fig. 6).
In summary, uEV have a unique proteomic compo-
sition that is biologically distinct from other biological
components present in the biofluid.
Urine from prostate cancer patients is enriched in
prostate cancer tissue-specific EV
Matched urine and radical prostatectomy tissue samples
from prostate cancer patients were collected, followed by
uEV and TCM EV separation. Viability and structure of
the prostate cancer tissue after TCM collection was con-
firmed by histological analysis (Suppl. fig. 7a).
Implementation of complementary NTA, TEM and wes-
tern blot analysis confirmed the separation of TCM EV
positive for ALIX, Flotillin-1, CD9 and Syntenin-1 from
GM130 and PMP70 contaminants (Suppl. fig. 7b-d).
Matched uEV and TCM EV (n = 3) were characterized
by mass spectrometry-based proteomics (LC-MS/MS).
The majority of proteins identified in TCM EV (Suppl.
table 3) was also present in matched uEV (1303/1376;
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94.69%), indicating that urine is a suitable biofluid for
studying clinical and biological aspects of prostate can-
cer-derived EV. In addition, enrichment maps of the
overlapping proteome between uEV and TCM EV
(Suppl. fig. 8–9) independently validated the biological
functions and cellular locations identified to be enriched
in uEV (Figure 3; Suppl. Fig. 5). While PCA, hierarchical
clustering and volcano plot analysis of the whole pro-
teome of both uEV and TCM EV showed differential
clustering, individual protein analysis revealed proteins
of bladder (UPK1B, UPK2) and kidney (PODXL, AQP2,
SLC12A1, etc.) origin in uEV, whereas TCM EV and
uEV were equally enriched in prostate-specific markers
(KLK2, KLK3/PSA, FOLH1, etc.) (Suppl. fig. 10).
Figure 2. Technical evaluation of BU ODG fractionation of urine by mass spectrometry-based proteomic analysis (LC-MS/MS). LC-MS/MS
data from EV-, THP- and protein-enriched fractions are compared by (a) correlation analysis, (b) anosim analysis, (c) hierarchical clustering,
(d) principle component analysis, (e) venn diagram, (f) spectral counting of EV-associated proteins (CD9, CD63, CD81, ALIX (PDCD6IP),
TSG101, FLOT1, SDCBP, EZR, MSN, ANXA1, ANXA2) and urinary high-abundance proteins (THP, ALB, IGHA1, IGHG1-4, IGHM, TF, HP, A2M,
FGA, ORM, complement factors and apolipoproteins) and (g) volcano plot analysis. In (a), correlation is represented as Pearson’s
r coefficient. In (g), exemplary proteins of interest are highlighted in black and prostate-specific markers in red.
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EV separated from urine can be interrogated for
prostate cancer markers
Urine from men with prostate cancer prior to (n = 12)
and after local treatment (n = 10), and urine from
healthy controls with BPH (n = 12), was fractionated
in EV- and protein-enriched fractions, which were
analysed by LC-MS/MS. Patient and tumour character-
istics are summarized in Table 1.
In total, 3686 and 1996 proteins were, respectively,
detected in EV-enriched (Suppl. table 4) and protein-
enriched fractions (Suppl. table 5) of all groups. Of
these, 3552 (96.36%) and 1913 (95.84%) proteins
were, respectively, identified in urine samples from
prostate cancer patients prior to treatment.
Using these data, a group of 684 proteins was iden-
tified as putative contaminants of uEV preparations
based on their selective identification in protein-
enriched fractions only (Suppl. table 6). Pathway
enrichment analysis of these contaminating proteins
revealed their involvement in non-EV associated bio-
logical pathways (Suppl. fig. 11), independently validat-
ing our previous observations (Figure 3; Suppl. Fig. 5).
Overall, 1134 proteins, including several prostate
cancer markers (e.g. KLK3/PSA, FOLH1, TMPRSS2),
were detected and quantified in uEV from all 12 pros-
tate cancer patients (Figure 4(a)), while the number of
proteins detected in corresponding protein-enriched
fractions was lower (489 proteins) (Figure 4(b)).
Coverage of membranous prostate cancer markers
(e.g. FOLH1, PSCA) was higher in uEV samples,
while secreted prostate cancer markers (e.g. KLK3/
PSA, MSMB) were more abundant in protein-
enriched samples. Proteins were separated into quar-
tiles based on their median abundance (Figure 4(c,d)).
As described previously in prostate cancer tissue ana-
lyses [38,39], low-abundance proteins were observed in
a lower number of patients. Several proteins encoded
by prostate cancer driver genes [40–42], including
HRAS, AKT1, CUL3, NKX3-1 and PTEN, were detected
exclusively in uEV of multiple prostate cancer patients,
while others, such as CDH1 and SPINK1, were detected
exclusively in protein-enriched fractions. Prostate can-
cer drivers shared by both fractions, like KRAS, IDH1
and GSTP1, had a generally lower abundance in pro-
tein-enriched fractions or were identified in a smaller
Table 1. Patient and tumour characteristics. Abbreviations: PSA: prostate-specific antigen, cc: clear
cell renal cell carcinoma, pRCC: papillary renal cell carcinoma, chRCC: chromophobe renal cell
carcinoma.
Prostate cancer
(n = 12)
Benign prostatic hyperplasia
(n = 12)
Bladder cancer
(n = 5)
Renal cancer
(n = 6)
Age (years)
Median
(range)
70.5
(54–78)
64.5
(51–78)
69
(65–81)
61
(50–70)
Baseline PSA (ng/mL)
Median
(range)
8.9
(4.2–13.9)
2.8
(1.0–10.4)
Post-treatment PSA
(ng/mL)
Median
(range)
0
(0–2.09)
Gleason score, n (%)
≤6
7
≥8
3 (25.0%)
5 (41.7%)
4 (33.3%)
Tumour stage, n (%)
Ta
T1
T2
T3a
T3b
T4
–
0 (0%)
7 (58.3%)
3 (25.0%)
2 (16.7%)
0 (0%)
1 (20%)
1 (20%)
2 (40%)
1 (20%)
0 (0%)
0 (0%)
–
4 (66.7%)
0 (0%)
1 (16.7%)
0 (0%)
1 (16.7%)
Nodal stage, n (%)
N0
N1
11 (91.7%)
1 (8.3%)
4 (80%)
1 (20%)
4 (66.6%)
2 (33.3%)
Local treatment, n (%)
Radical
Prostatectomy
Radiotherapy
7 (58.3%)
5 (41.7%)
Histological subtype
ccRCC
pRCC
chRCC
3 (50%)
2 (33.3%)
1 (16.7%)
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number of patients (Figure 4(c,d)). As expected, pro-
tein products from nuclear transcription factors such as
ETS family members, or DNA repair genes (e.g. ATM,
BRCA1/2) could not be detected in either urinary
fraction.
The composition of the EV-enriched (Figure 5(a))
and protein-enriched (Figure 6(a)) urinary proteome
changed significantly after local prostate cancer treat-
ment, with a significant reduction in prostate (cancer)-
specific proteins (e.g. KLK2, KLK3/PSA, FOLH1,
MSMB, ACPP, TGM4, NDRG1, NKX3-1) and andro-
gen-regulated genes (e.g. FKBP5, FAM129A, RAB27A,
FASN, NEFH) [43,44] after prostatectomy or radiation
(Figures 5(b) and 6(b)). Conversely, post-treatment
samples were significantly enriched in EV containing
proteins from bladder (e.g. UPK1B, UPK3B) and kid-
ney origin (e.g. PODXL, AQP2, CA4, SLC12A1,
SLC12A3, GGT1, KCNJ1, NPHS1) (Figure 5(b)) [45].
In order to identify cancer-specific protein signatures,
EV-enriched (Figure 5(c)) and protein-enriched
(Figure 6(c)) urine samples, fractionated from men
diagnosed with benign prostate hyperplasia (n = 12)
were compared with those from prostate cancer
patients (n = 12). A comparative LC-MS/MS analysis
identified 705 differentially enriched proteins in uEV
fractions (Figure 5(d)) and 100 in protein-enriched
fractions (Figure 6(d)) which were also more abundant
in pre-treatment compared to post-treatment samples.
Biological pathway analysis of uEV-enriched proteins
in prostate cancer (Figure 7; Suppl. table 7) demon-
strated involvement in cancer-associated biological
processes such as protein and nucleic acid biosynthesis,
autophagy and macromolecule turnover and immune
system activation [46]. In contrast, no additional
Figure 4. Quantitative protein distribution in EV-enriched and protein-enriched urine fractions from prostate cancer patients. The
bar chart shows total counts of proteins detected in a certain number of patient samples for: (a) EV-enriched fractions and (b)
protein-enriched fractions. The number on the first bar represents the number of proteins detected in all 12 samples. Protein
distribution is measured as Log2 median intensity per protein to the number of patient samples in which it is detected for: (c) EV-
enriched fractions and (d) protein-enriched fractions. Colours represent protein abundance in quartiles. Prostate cancer-related
proteins are highlighted.
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information on prostate cancer biology could be with-
held from differentially enriched proteins in protein-
enriched fractions (Suppl. fig 12; Suppl. table 8).
Finally, the uEV proteome ofmenwith prostate cancer
was compared to that of patients with other urological
cancer types (n = 11), which further confirmed selective
enrichment of protein signatures in uEV reflecting their
respective cancer tissues of origin (Figure 8(a)) [45].
Specifically, uEV from patients with renal cancer (RCC)
were enriched in several proteins overexpressed in RCC
(e.g. EGFR, ENPEP, TMEM52B, BBOX1, RBP5, AQP1)
compared to other cancers (Figure 8(b)) [45,47–49].
Similarly, bladder cancer uEV were shown to be enriched
in UCC-associated proteins (e.g. UPK1A, UPK1B, UPK2,
UPK3B) (Figure 8(c)) [45,50]. This could not be observed
for protein-enriched fractions (data not shown). The pre-
sence of selected prostate- (PSA/KLK3), kidney- (PODXL,
SLC12A1, AQP2) and bladder-derived (UPK1B) proteins,
as well as biologically relevant proteins involved in pros-
tate cancer pathogenesis (FASN, IDH1, RAB27A) in uEV
was independently confirmed by immunoblotting
(Figure 8(d)).
Discussion
A repeatable separation method with high specificity is
essential to explore EV-specific functions and biomar-
kers [8,13,22].
We provide a comparative evaluation of the three
most commonly implemented methods to separate EV
Figure 5. Mapping of the prostate cancer proteome in EV-enriched fractions. LC-MS/MS data from EV-enriched fractions from
prostate cancer patients pre- and post-treatment are compared by (a) principle component analysis and (b) volcano plot analysis.
Proteins related to prostate (pre-treatment) and bladder and kidney (post-treatment) tissue are highlighted. (c) LC-MS/MS data from
EV-enriched fractions from patients with benign prostatic hyperplasia (BPH) and prostate cancer (PC) as compared by principle
component analysis. (d) Venn diagram displaying EV-enriched proteins enriched in prostate cancer EV prior to treatment versus
after treatment and versus benign prostatic hyperplasia.
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from urine: DUC, SEC and EQ (Suppl. fig. 1). Multiple
observations indicate that all three methods separate
EV with low specificity due to co-isolation of THP
protein complexes. Although well established in the
EV research field [12], the tendency of DUC to co-
isolate non-EV-associated high-molecular weight pro-
teins and protein complexes [22,51–53], as well as its
relatively low recovery efficiency (between 1% and 5%
in this study) are widely recognized [19,54–56]. In
addition, EV are potentially damaged during the final
ultracentrifugation step [57]. SEC-based EV separation
has been proposed as a quick and easy method to
obtain omics-grade uEV preparations in clinical set-
tings. Although this method separates uEV from the
bulk of soluble proteins with a recovery efficiency of
nearly 60%, residual contamination with abundant
urinary proteins remains (Suppl. fig. 2 and 4c). This is
reflected in lower numbers of identified proteins in
proteomic studies using SEC-based uEV separation
[24,58,59]. Although EQ has a high efficiency to
retrieve EV [19], it has been demonstrated that this
method co-isolates non-EV associated high-molecular
Figure 6. Mapping of the prostate cancer proteome in protein-enriched fractions. LC-MS/MS data from protein-enriched fractions
from prostate cancer patients pre- and post-treatment are compared by (a) principle component analysis and (b) volcano plot
analysis. Proteins related to prostate (pre-treatment) tissue are highlighted. (c) LC-MS/MS data from protein-enriched fractions from
patients with benign prostatic hyperplasia (BPH) and prostate cancer as compared by principle component analysis. (d) Venn
diagram displaying proteins enriched in protein-enriched urine fractions in prostate cancer patients prior to treatment versus after
treatment and versus patients with benign prostatic hyperplasia (BPH).
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weight proteins and protein complexes that mask the
identification of the uEV proteome [22,60].
To overcome the limitations of the most commonly
implemented EV separation methods, we introduce
density-based fractionation of urine. Our study pro-
vides substantial evidence supporting the use of a BU
ODG to separate EV, THP protein complexes and
soluble proteins with high specificity from urine of
healthy donors and patients diagnosed with prostate
cancer, bladder cancer and renal cancer for biomarker
discovery. Complementary observations confirmed
a highly specific fractionation of urine in an EV-
enriched fraction, characterized by a density of
1.087 g/mL – 1.109 g/mL containing uEV, and a pro-
tein-enriched fraction, characterized by a density of
1.207 g/mL – 1.231 g/mL containing soluble proteins
and protein complexes. BU ODG recovered EV from
urine with 30% efficiency (Suppl. fig. 4c). EV-enriched
fractions obtained by BU ODG show a 16.5-fold,
4.0-fold, 2.1-fold and 1.1-fold enrichment of particle
to protein compared to EQ, SEC, DUC and TD ODG
(Suppl. fig. 13). Thus, BU ODG separates uEV with
Figure 8. Differences between the urinary EV proteome from men with prostate cancer, renal cancer and bladder cancer. LC-MS/MS
data from EV-enriched fractions from prostate, renal and bladder cancer patients are compared by (a) principle component analysis
and (b–c) volcano plots. Proteins related to prostate, renal or bladder tissue are highlighted. (d) Western blot validation of selected
prostate (cancer)-, kidney- and bladder-enriched proteins in urinary EV.
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the highest specificity compared to the most com-
monly implemented methods and simultaneously pro-
vides the opportunity to explore both EV-enriched
fractions and protein-enriched fractions for biomar-
ker discovery (Figure 1(e)).
Indeed, mass spectrometry-based proteomics
revealed enrichment of cytosolic and membrane-
derived proteins implicated in EV biogenesis, protein
and nucleic acid metabolism, signalling and cytoskele-
ton homeostasis in the EV-enriched fraction, while cell
adhesion, proteolysis, innate immune response, platelet
degranulation and extracellular matrix organization
pathways were enriched in the protein-enriched frac-
tion (Figure 3, Suppl. fig. 5).
Pre-analytical variables in urine processing procedures
such as urine collection and storage, and addition of
protease inhibitors or chemical agents significantly vary
between studies [5]. Although the potential impact of
these factors during clinical sample processing on EV
studies is increasingly recognized [61], only few have
been undertaken using urine [18,62]. For this
study, second morning samples from fasting donors
were used, omitting urine collection from bladder resi-
dues and eliminating dietary interference on urine com-
position. Bacterial contamination, urinary tract infection,
haematuria and proteinuria may affect downstream ana-
lysis of uEV [63–65]. Only fresh urine samples with
normal values for erythrocytes, protein and nitrite/leuko-
cytes based on strip testing were included in the study.
Protease inhibitors were not added, since uEV were
demonstrated to be largely resistant to the endogenous
proteolytic activity of urine [66]. Clinical urine samples
from men with prostate cancer and BPH were collected
following DRE, which is generally considered as a critical
factor in prostate biomarker studies because it enriches
for prostate-derived secretions. This may be especially
advantageous for the detection of low-abundance bio-
markers. However, omission of DRE in the urine collec-
tion process could be beneficial for standardizing
collection procedures, removing a certain level of varia-
bility introduced by this procedure. Clinical biomarker
studies should, therefore, attempt to validate biomarker
detection in urine collected without prior DRE, given this
does not negatively influence detection sensitivity [67].
The treatment of urine or uEV with the reducing agent
dithiothreitol (DTT), zwitterionic detergent CHAPS or
urea to denature and remove abundant THP has pre-
viously been proposed [68–70]. However, this study
demonstrated no significant advantage of DTT treatment
on reducing THP contamination or increasing uEV yield
when applying a BU ODG. In addition, EV-associated
proteins may also be reduced when using DTT, hamper-
ing correct folding and functionality, potentially leading
to loss of biomarker promise [69]. Finally, normalized
analysis of EV in urine is challenging due to variation of
uEV concentration because of fluid intake and renal
function. It is not clear whether the intrinsic inter- and
intrasubject variability of urine is also reflected in uEV
[5]. In our study, variations in uEV yield did not correlate
well to urinary creatinine levels (Spearman’s ρ = 0.59;
p = 0.003) (Suppl. fig. 14a). Instead, we used uEV protein
to normalize for uEV yield in proteomics experiments
due to its superior correlation to particle count in EV-
enriched fractions (Spearman’s ρ = 0.94; p < 0.0001) than
urinary creatinine (Suppl. fig. 14b).
Unbiased assessment of the performance of EV separa-
tion from urine in terms of technical and methodological
repeatability is currently missing in the literature [5,8],
Table 2. Overview of previous proteomic studies in urinary EV.
Study (year)
EV-TRACK
ID Phenotype
Separation
method(s)
Protein
identifications*
Contaminants
(%)***
EV-METRIC
(%) Reference
Smalley et al. (2008) NA Healthy control DUC 322 7 (2.17%) 22 [65]
Gonzales et al. (2009) NA Healthy control; Bartter Syndrome DUC 1060 40 (3.77%) 14 [68,74]
Chen et al. (2012) EV120030 Healthy control; Bladder Cancer DUC 616 12 (1.95%) 33 [71]
Raimondo et al.
(2013)
EV130016 Healthy control; Renal Cancer DUC 261 10 (3.83%) 44 [72]
Principe et al. (2013) EV130224 Healthy control; Prostate Cancer DUC 877 139 (15.85%) 14 [75]
Øverbye et al. (2015) EV150029 Benign Prostatic Hyperplasia;
Prostate Cancer
DUC 1664 NP 33 [73]
Lozano-Ramos et al.
(2015)
EV180054 Healthy control UF + SEC 138 NP 14 [24]
Oeyen et al. (2018) EV170025 Healthy control UF + SEC 423 9 (2.13%) 62 [58]
Vesiclepedia NA Multiple Multiple 4788** 274 (5,72%) NA [76]
Dhondt et al. (2020) EV190064 Benign Prostatic Hyperplasia;
Prostate Cancer
UF + BU ODG 3686 NA 100 This
study
* Protein identification based on at least two detected peptides, FDR of 0.01 and availability of UniprotKB identifier
** Known uEV proteome with protein identification based on variable parameters [76]
*** Number of contaminants based on the list of putative contaminants of uEV preparations compiled in this study (Suppl. table 4). This does not include
urinary high-abundance proteins co-separated with uEV.
NA: not available/applicable
NP: dataset not public
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impeding the potential utility of EV-derived biomarkers to
asses biological processes [16]. The implementation of
density-based fractionation requires technical expertise
and might be prone to replication bias. Proteomic analysis
of EV-enriched and protein-enriched fractions obtained by
BU ODG performed in six technical replicates showed
a high methodological repeatability (Figure 2). Recent
advances in robot-assisted gradient preparation increase
the repeatability of density-based fractionation [21].
Furthermore, the use of reference materials such as track-
able recombinant EV will assist in mitigating technical
variation introduced during sample preparation and ana-
lysis [19].
We implemented the BU ODG fractionation strategy
to perform the most comprehensive analysis of the uEV
proteome in men with benign and malignant prostate
disease to date. Overall, we identified a total of 3686
proteins, which represents a more than twofold increase
relative to previously published uEV proteomes
[24,58,65,71–75], adding, with high specificity, hundreds
of proteins to the known human uEV proteome [76]
(Table 2 and Suppl. fig. 15). Identified proteins include
proteins encoded by prostate cancer driver genes such as
NKX3-1 and PTEN, known prostate cancer markers like
FOLH1/PSMA and KLK3/PSA and androgen-regulated
genes like FKBP5 and FAM129A, among others.
Amore elaborate comparison of our dataset to previously
published ones is complicated due to technical differences
in pre-analytical urine collection and processing, EV iso-
lation and LC-MS/MS sample preparation, procedure
and bio-informatic data processing.
Next, we implemented multiple approaches to con-
firm the specificity of the identified uEV proteome for
prostate cancer. We separated EV from conditioned
medium prepared from prostate cancer tissue (Suppl.
fig 7–10) and implemented mass spectrometry-based
proteomics to establish the EV proteome of prostate
cancer tissue (Suppl. table 3). TCM EV protein signa-
tures were detectable in matched uEV protein signa-
tures hinting towards the identification of prostate
cancer-related uEV and demonstrating the suitability
of urine as a proximal fluid for studying prostate can-
cer-derived EV. Differential analysis of the EV pro-
teome from urine samples collected from patients
with benign prostate hyperplasia and prostate cancer
prior to and after treatment selectively identified can-
cer-associated biosynthetic and catabolic pathways in
uEV obtained from prostate cancer patients prior to
treatment (Figure 7). Of note, differential analysis of
matched protein-enriched fractions resulted in
restricted pathway identification. Several proteins com-
monly overexpressed in prostate cancer tissue were
selectively enriched in uEV from prostate cancer
patients prior to treatment versus after treatment and
versus men with benign prostate hyperplasia (Suppl.
Table 7). These include proteins involved in prostate
cancer progression, such as the metalloreductase
STEAP2 [77], nuclear export protein XPO1 [78] and
citrate metabolic enzyme IDH1 [79]. Enzymes involved
in the dysregulated lipid metabolism observed in pros-
tate cancer, like FASN and FABP5 [80,81] were also
enriched in uEV. In accordance with our observations,
XPO1 and FASN have previously been described to be
upregulated in EV separated from prostate cancer cell
lines [82]. Other markedly enriched proteins in pros-
tate cancer uEV were Rab GTPases (e.g. Rab7A,
Rab27A, Rab27B, etc.), Myosin isoforms (e.g. MYO1E,
MYO5A, MYO5C, MYO6, etc.), proteasomal and ribo-
somal proteins. Many Rab proteins have been shown to
be involved in EV biogenesis and are typically identi-
fied in EV [7]. Rab27, involved in exocytosis [83],
drives invasive growth and metastasis in multiple can-
cer types [84,85]. Myosins are a family of actin-
dependent motor proteins important for cell migration
and motility. They are also responsible for cellular EV
transport and release [7]. Several myosins, including
MYO5A, MYO5C and MYO6, have been found to be
overexpressed in prostate cancer and involved in can-
cer cell migration [86,87]. Finally, using a set of urine
samples from patients diagnosed with urological can-
cers other than prostate cancer, we provided additional
evidence of the selective enrichment of protein signa-
tures in uEV reflecting their respective cancer tissues of
origin. uEV from patients with renal cell carcinoma
were enriched in EGFR, of which overexpression is
associated with an unfavourable histologic phenotype
[47], ENPEP, involved in renal cell carcinoma angio-
genesis [88], and AQP1, a water-channel protein sig-
nificantly upregulated in clear cell and papillary renal
cell carcinoma [49], amongst other proteins, compared
to prostate cancer uEV. On the other hand, bladder
cancer uEV were enriched in multiple uroplakins
(UPK1A, UPK1B, UPK2, UPK3B), transmembrane pro-
teins specifically expressed in urothelium and overex-
pressed in bladder cancer [50]. Although this small and
heterogenous cohort of renal and urothelial cell carci-
nomas patients was sufficient to demonstrate global
differences between uEV of different cancer types, the
main research focus of this study was prostate cancer.
Therefore, efforts to map the biological role and clin-
ical potential of uEV in other cancer types should be
the subject of future research.
While BU ODG fractionation proved to meet neces-
sary standards of reliability and repeatability for EV
biomarker discovery, the long turn-around time and
low-throughput aspect of a density gradient approach,
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as well as the need for relatively high sample volumes,
limits its use beyond a scientific research setting. We,
therefore, propose BU ODG as a standardized method
for uEV biomarker discovery, followed by clinical assay
development from validated biomarker candidates with
clinical value. Microfluidic chip-based technologies,
capable of integrated EV separation and analysis, sig-
nificantly lower the limit of detection, sample volume
and analysis time, and might be the key in facilitating
the realization of EV-based assays in clinical laboratory
and point-of-care settings [5].
Despite the high need, a list of EV contaminants is not
yet available to the EV research community [8,13]. BU
ODG fractionation applied in this study provides
a unique experimental set-up to compile a list of contami-
nants for uEV based upon differential analysis of EV-
enriched fractions versus protein-enriched fractions. We
propose a list of 684 putative contaminants of uEV pre-
parations based on their unique identification in the pro-
tein-enriched fractions (Suppl. table 6). Of note, abundant
proteins such as Tamm-Horsfall Protein (THP/UMOD)
and serumalbumin (ALB), and several lipoproteins, immu-
noglobulins and complement factors, are not part of this
list of proteins. Despite their abundant enrichment in
protein-enriched fractions compared to EV-enriched frac-
tions, their identification is not exclusive to protein-
enriched fractions. THP is synthesized by the kidney in
the distal convoluted tubules and thick ascending limbs of
Henle. Despite its abundance in urine as a high-molecular-
weight polymer, monomeric THP is expressed on the
luminal surface of kidney epithelial cells as
a glycosylphosphatidylinositol (GPI)-linked membrane
protein [89]. Therefore, monomeric THP might be
a normal constituent of uEV. Alternatively, the co-
separation of secretory proteins in EV-enriched fractions
might indicate the presence of a protein corona on uEV
[8,90], adding an additional layer of complexity towards
identifying true uEV content. Although outside the scope
of this study, future research on such a potential in vivo EV
corona might enhance our understanding of the interac-
tion between EV and soluble factors in biofluids.
In conclusion, we developed a density-based fractio-
nation method for EV separation from urine with high
specificity and methodological repeatability. Our
approach is applicable to urine samples from multiple
clinical conditions. Proteomic analysis of uEV demon-
strates that their content mirrors the cytosolic and
membrane-bound protein composition of the cells
they are derived from. uEV are enriched in multiple
prostate cancer markers, oncogenic drivers and andro-
gen-regulated gene products, and provide additional
insight into cancer-specific biological processes com-
pared to the soluble urinary proteome. Although
disparate uEV protein signatures across several clinical
conditions could be identified, this study was not pow-
ered for biomarker discovery. Nonetheless, this
research represents a thoroughly substantiated case
that favours further efforts to map the proteomic con-
tent of uEV, separated from prospectively collected
clinical samples from well-defined patient cohorts, to
generate new candidate biomarkers with potential
diagnostic and prognostic value in prostate cancer.
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